ALN-5288 (MAPT) Investigational RNAi therapy targeting microtubule-associated protein tau, undergoing partnered Phase 1 development for Alzheimer’s disease and related tau-driven neurodegeneration.
Visit productCosigns Received
Be the first Cosign
Put your name behind ALN-5288 (MAPT).
Add it to your Products I use list and share why you use it.